DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for premature ovarian failure 7 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePremature ovarian failure 7 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for premature ovarian failure 7 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
nuclear receptor subfamily 5 group A member 1 (NR5A1) — NR5A1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4QJR · 2.4 Å · ligand (2S)-3-{[(R)-{[(1S,2S,3R,4S,5S,6S)-2,6-dihydroxy-3,4,5-tris(phosphonooxy)cyclohexyl]oxy}(hydroxy)phosphoryl]oxy}propane
-1,2-diyl dihexadecanoate (PIZ). Experimental structure, not a prediction.
What the evidence adds up to
Premature ovarian failure affects roughly 1 in 100 women, defined by amenorrhea, low oestrogen, and high gonadotrophins before age 40. A 1982 case report describes a 26-year-old woman with four years of primary infertility whose cycles had been 21–25 days since menarche at age 11, with light flow and moderate dysmenorrhea; she had taken a mestranol-norethindrone oral contraceptive for four years before infertility began. That report notes the diagnosis is rarely suspected before menstruation stops entirely, and presents the case as an unusual chance to observe the condition developing over two years.
Genetic causes are well recognised, and one laboratory reports having identified several candidate genes associated with POF. A 2024 review states the aetiology and pathogenesis may involve genetic, immunological, medical, environmental, infectious, psychological, and enzyme-deficiency factors. The same review lists treatment approaches that include Western medicine, Chinese medicine, a combination of both, and interventions at hormone, cellular, surgical, and psychological levels, but provides no numerical outcomes—no response rates, no survival data, no sample sizes.
No abstract reports a drug that reverses or halts premature ovarian failure. The 2024 review is a narrative summary of progress, not a controlled trial. What is missing are prospective studies with clearly defined patient stratification, adequately funded randomised trials testing any single intervention against placebo or standard care, and long-term follow-up that reports live birth rates or sustained ovarian function rather than surrogate hormone levels.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Australian and New Zealand Journal of Obstetrics and Gynaecology · 2006 · 126 citations
The genetic basis of premature ovarian failure
AbstractPremature ovarian failure (POF) is a common condition, affecting approximately 1:100 women. It is characterised by amenorrhea, hypoestrogenism, and elevated gonadotrophin levels in women under the age of 40. It is often an unexpected and distressing diagnosis, which coincides with infertility and menopausal symptoms. There is a well recognised genetic basis to the development of POF. Our laboratory has identified several candidate genes associated with POF.
Luteal Phase Defect as a Marker of Imminent Ovarian Failure
AbstractThe diagnosis of premature ovarian failure is rarely suspected before complete cessation of menstrual function. Consequently, there is little in the literature regarding its antecedent history. The case here presented affords an unusual opportunity to observe the development of premature ovarian failure over a 2-year period.A 26-year-old married women presented in February, 1978 with a history of primary infertility of 4 years' duration. Since menarche at age 11, the patient's cycles had ranged from 21 to 25 days in length, with light menstrual flow and moderate dysmenorrhea. She had taken a mestranol-norethindrone oral contraceptive for 4 years before the onset of infertility.
Journal of Clinical and Nursing Research · 2024 · 0 citations · open access
Recent Research Progress in Premature Ovarian Failure
AbstractPremature ovarian failure refers to ovarian function failure in women before the age of 40 years due to follicular depletion or follicular dysfunction resulting in abnormal hormone levels. The etiology and pathogenesis of premature ovarian failure may be related to genetic, immunological, medical, environmental, infectious, psychological and enzyme deficiencies. The treatment involves Western medicine, Chinese medicine, and a combination of Chinese and Western medicine, and the treatment level includes hormone level, cellular level, surgery and psychological aspect. This paper would like to review the progress of the etiology, pathogenesis and treatment of premature ovarian failure in recent years.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
